SLCO1B1 and short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome: Preemptive SLCO1B1 pharmacogenetic (PGx) testing may diminish the incidence of SAMS by identifying individuals with increased genetic risk before statin initiation.